Small molecule · developed by Lakefront Biotherapeutics NV
GLPG2737 is an orally administered capsule drug studied in autosomal dominant polycystic kidney disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04578548 | Phase 2 | Autosomal Dominant Polycystic Kidney Disease | Terminated | LKFT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Autosomal Dominant Polycystic Kidney Disease
Updated Oct 18, 2026. Something wrong or missing? Report it on the LKFT page.
See LKFT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LKFT catalysts and pipeline →